Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177917 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Georgeta Liliana Foia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2D) is a major and growing global health burden that is associated with substantial cardiovascular, renal, and metabolic complications and is increasingly recognized as a systemic disorder involving multiple organs, particularly the liver. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than half of individuals with T2D, and the two conditions have a bidirectional relationship: T2D promotes the development and progression of MASLD, including advanced fibrosis and increased liver-related mortality, while MASLD worsens insulin resistance and metabolic control, favoring the onset of T2D. In this context, the liver is increasingly viewed not only as a metabolic organ but also as an endocrine one, secreting hepatokines that act on distant tissues to regulate insulin sensitivity, inflammation, glucose metabolism, and lipid homeostasis. Through these actions, hepatokines are thought to represent one of the mechanistic links between MASLD and T2D. This narrative review summarizes current evidence on several of the most extensively studied hepatokines, including fibroblast growth factor 21, fetuin-A, fetuin-B, leukocyte cell-derived chemotaxin-2, selenoprotein P, angiopoietin-like proteins, and retinol-binding protein 4. As a distinctive feature, the review also discusses emerging pharmacological strategies targeting hepatokine pathways and evaluates how commonly used antidiabetic therapies may modulate hepatokine secretion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- University of Medicine and Pharmacy, 200349 Craiova, Romania.
ORCID-Profile: Georgeta Liliana Foia, Ancuta Goriuc, Ionut Luchian, Dana Gabriela Budala, Maria Bogdan, Bogdan Minea, Larisa Ghemiș
Zitieren
APA
Foia, G. L., Goriuc, A., Luchian, I., Budala, D. G., Toma, V., Bogdan, M., Minea, B., & Ghemiș, L. (2026). Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177917
Vancouver
Foia GL, Goriuc A, Luchian I, Budala DG, Toma V, Bogdan M, et al. Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177917
BibTeX
@article{Foia2026,
author = {Foia, Georgeta Liliana and Goriuc, Ancuta and Luchian, Ionut and Budala, Dana Gabriela and Toma, Vasilica and Bogdan, Maria and Minea, Bogdan and Ghemiș, Larisa},
title = {Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177917}
}
EUVIMED